From the Editor

For obese postmenopausal women, what options may decrease endometrial cancer risk?

Author and Disclosure Information

 

References

Progestin treatment and endometrial cancer risk

Estrogen stimulates endometrial cell proliferation. Hence, unopposed chronic exposure to estrogen is a major risk factor for developing endometrial hyperplasia and cancer. Progestins block the proliferative effect of estrogen and cause cell differentiation, resulting in stromal decidualization. Progestins also reduce the concentration of estrogen and progesterone receptors and increase the activity of enzymes that convert estradiol to estrone, blocking estrogen-induced endometrial proliferation.14

In women with endometrial hyperplasia, progestins have been shown to be effective in resolving the hyperplasia in approximately 80% of cases. Both oral progestins and the 52-mg levonorgestrel-containing intrauterine device (LNG-IUD) have been reported to be effective in the treatment of endometrial hyperplasia. In a Cochrane systematic review and meta-analysis, the 52-mg LNG-IUD was reported to be somewhat more effective in resolving endometrial hyperplasia than cyclic oral progestins (89% vs 72%, respectively).15

Other studies have also reported that the 52 mg LNG-IUD was more effective than oral progestin therapy for women with complex atypical endometrial hyperplasia.16 There are no large randomized clinical trials of progestin therapy on prevention for future development of endometrial cancer in obese postmenopausal women who have a normal endometrial histology. However, for an obese perimenopausal woman, insertion of a 52-mg LNG-IUD may help to minimize excessive uterine bleeding during the menopause transition and reduce the risk of developing endometrial hyperplasia during the early postmenopause.

We can help our patients reduce their risk of endometrial cancer

Obese postmenopausal women are at increased risk for developing endometrial cancer. Gynecologists play an important role in the prevention and early detection of endometrial cancer. We can make a difference and improve the health of our obese peri- and postmenopausal women by recommending interventions that reduce the risk of endometrial cancer, thereby improving the health of our patients. ●

Pages

Recommended Reading

Two-stage surgery to reduce ovarian cancer risk piques interest
MDedge ObGyn
Are uterine manipulators safe for gynecologic cancer surgery?
MDedge ObGyn
New technologies aim to improve ovarian cancer detection
MDedge ObGyn
9vHPV vaccine: Prevention of oropharyngeal cancer
MDedge ObGyn
Rare event: Iatrogenic injury during cervical cancer screening
MDedge ObGyn
Low threshold to biopsy atypical lesions may ID vulvar melanoma early, experts say
MDedge ObGyn
Two-drug combo should be first-line standard of care in advanced endometrial cancer
MDedge ObGyn
Half of women treated for gynecologic cancers miss or skip doses of oral drugs
MDedge ObGyn
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
MDedge ObGyn
Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy
MDedge ObGyn